RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Darapladib without Significant CV Benefit in Stable Coronary Heart Disease (STABILITY)
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 4
SP 14
OP 15
DO 10.1177/155989771404004
UL http://mdc.sagepub.com/content/14/4/14.2.abstract
AB An investigational, selective, orally active inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) failed to significantly reduce the risk for cardiovascular death, myocardial infarction, or stroke in stable coronary heart disease patients on optimal medical therapy. The design and results of the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy trial [STABILITY; The STABILITY Investigators. N Engl J Med 2014] are discussed in this article.